The FY22 PCRP Translational Science Award mechanism supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the FY22 PCRP Overarching Challenges. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside, but can include a reciprocal flow of ideas and information between basic science and clinical science (bench to bedside and/or bedside to bench).
This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following: • Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts (The Translational Science Award is not intended to support initial mechanistic studies of a new target.) • Late-stage preclinical work leading to/preparing for a clinical trial, e.g., an Investigational New Drug application submission • Correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trials to improve clinical management of prostate cancer and/or define new areas of research • Projects that develop endpoints for clinical trials
Deadlines:
• Required Pre-Application Deadline: Aug. 4, 2022
• Application Submission Deadline: Aug. 25, 2022
The Mission of the FY22 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service Members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following FY22 PCRP Overarching Challenges:
• Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer
• Develop treatments that improve outcomes for men with lethal prostate cancer
• Advance health equity and reduce disparities in prostate cancer
• Define the biology of prostate cancer progression to lethal prostate cancer to reduce death
Each investigator may be named on only one FY22 PCRP Translational Science Award application as a PI, Initiating PI, or Partnering PI.
Independent investigators at all levels are eligible to be named as PI, Initiating PI, or Partnering PI on an application for the FY22 PCRP Translational Science Award.
The anticipated direct costs budgeted for the entire period of performance for an FY22 PCRP Translational Science Award will not exceed $900,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
